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Abstract
TP53INP2 positively regulates autophagy by binding to Atg8
proteins. Here, we uncover a novel role of TP53INP2 in death-
receptor signaling. TP53INP2 sensitizes cells to apoptosis induced
by death-receptor ligands. In keeping with this, TP53INP2 defi-
ciency in cultured cells or mouse livers protects against death
receptor-induced apoptosis. TP53INP2 binds caspase-8 and the
ubiquitin ligase TRAF6, thereby promoting the ubiquitination and
activation of caspase-8 by TRAF6. We have defined a TRAF6-inter-
acting motif (TIM) and a ubiquitin-interacting motif in TP53INP2,
enabling it to function as a scaffold bridging already ubiquitinated
caspase-8 to TRAF6 for further polyubiquitination of caspase-8.
Mutations of key TIM residues in TP53INP2 abrogate its interaction
with TRAF6 and caspase-8, and subsequently reduce levels of
death receptor-induced apoptosis. A screen of cancer cell lines
showed that those with higher protein levels of TP53INP2 are more
prone to TRAIL-induced apoptosis, making TP53INP2 a potential
predictive marker of cancer cell responsiveness to TRAIL treatment.
These findings uncover a novel mechanism for the regulation of
caspase-8 ubiquitination and reveal TP53INP2 as an important
regulator of the death receptor pathway.
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Introduction
Apoptosis is a process of programmed cell death that is crucial for
the homeostasis of an organism, and its deregulation occurs in
several pathologies (Jacobson et al, 1999; Vaux & Korsmeyer,
1999). Apoptosis can be triggered through either an intrinsic or
extrinsic pathway (Ferri & Kroemer, 2001; Fulda & Debatin, 2006).
In the former, cellular damage is sensed by various Bcl-2 pro-apop-
totic homologues and leads to Bax/Bak oligomerization in the outer
mitochondrial membrane, release of cytochrome c, and apoptosome
formation, where caspase-9 is activated (Zou et al, 1999). Activated
caspase-9 cleaves caspases-3, -6, and -7, which execute apoptosis
(Zou et al, 1999). In the extrinsic pathway, death ligands (FasL,
TRAIL/Apo2L and TNFa) bind to their cognitive receptors and
induce their trimerization, thereby allowing subsequent binding of
the adaptor protein FADD and caspase-8 to the DISC complex
(death-inducing signaling complex; Medema et al, 1997). Caspase-8
was thought to be activated through the so-called proximity-induced
model, i.e., dimerization of pro-caspase-8 molecules in the DISC
complex. However, this model has recently been challenged by the
DED chain assembly model, which proposes that a FADD molecule
interacts with several caspase-8 molecules (Dickens et al, 2012;
Schleich et al, 2012). Activated caspase-8 directly cleaves execu-
tioner caspases (i.e., caspase-3) in type I cells (e.g., thymocytes),
while in type II cells (e.g., hepatocytes) it cleaves the Bcl-2 homol-
ogy domain 3 (BH3) protein Bid, producing tBid, which amplifies
the signal through mitochondria (Li et al, 1998; Luo et al, 1998).
Recently, several studies have added additional layers of complexity
to caspase-8 activation, revealing that ubiquitination plays a key
role in this process. For example, the E3 ubiquitin ligase cullin-3
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ubiquitinates caspase-8 at its C-terminus in the DISC complex and
ubiquitinated caspase-8 is aggregated by p62 for its full activation
(Jin et al, 2009). In contrast, TRAF2 adds K48-ubiquitin chains to
the large catalytic domain of caspase-8 and marks it for degradation
(Gonzalvez et al, 2012), while HECTD3 ubiquitination of the Lys
residue between the DED and the large domain of caspase-8
increases the threshold for death receptor-induced apoptosis (Li
et al, 2013).
One of the hallmarks of cancer cells is their capacity to evade
apoptosis. Most chemotherapies in clinical practice aim to induce
cell death in tumors, thus shrinking the tumors to a size that can be
removed by surgery, or to kill any remaining and/or circulating
tumor cells. Chemotherapy has several disadvantages. In addition to
not being effective in all or even in the majority of patients, it causes
side effects. This observation points to the need for personalized
medicine, i.e., the selection of patients that will respond and benefit
from a given chemotherapy. The initial optimism caused by the
discovery of TRAIL, for example, which selectively kills cancer cells,
plummeted after several unsuccessful clinical trials. Thus, better
antagonists and molecular markers to identify patients who would
respond to TRAIL are needed (de Miguel et al, 2016; von Karstedt
et al, 2017). This need is further emphasized by the observation that
tumors not undergoing apoptosis upon TRAIL administration can
diverge the signaling to cytokine production, thus favoring tumor
growth (Hartwig et al, 2017; Henry & Martin, 2017).
The complexity of the cross-talk between autophagy and apopto-
sis has been widely studied, not only with the purpose of under-
standing the underlying mechanisms, but also of modulating both
pathways in tumors. Several autophagic proteins have a dual role in
both processes (Yousefi et al, 2006; Cho et al, 2009; Giansanti et al,
2011). The inhibition of autophagy causes the accumulation of
autophagosomal membranes, which serve as platforms for intracel-
lular DISC formation (Laussmann et al, 2011; Pan et al, 2011;
Young et al, 2012; Huang et al, 2013). Canonical and intracellular
DISC formation occurs independently and requires distinct
membranes (Jiang et al, 2011; Laussmann et al, 2011; Pan et al,
2011; Young et al, 2012; Deegan et al, 2014). Thus, pro-caspase-8
binds to intracellular DISC on the phagophore through ATG12-
ATG5-FADD on the outer membrane or through LC3-p62 on the
inner membrane of the accumulating autophagosomes (Bell et al,
2008; Jiang et al, 2011; Laussmann et al, 2011; Pan et al, 2011;
Young et al, 2012; Huang et al, 2013; Deegan et al, 2014; Tang
et al, 2017). The LC3-p62 axis most probably recruits ubiquitinated
caspase-8 in a similar way as the autophagic cargo is recruited to
autophagosomes (Pankiv et al, 2007; Huang et al, 2013).
In proliferating cells, TP53INP2 is a nuclear protein that interacts
with nuclear hormone receptors (Baumgartner et al, 2007; Francis
et al, 2010), shuttles from the nucleus to the cytosol (Mauvezin
et al, 2010, 2012), and stimulates protein synthesis by promoting
ribosomal biogenesis in the nucleolus (Xu et al, 2016). However,
upon nutrient depletion, TP53INP2 interacts with a nuclear and
deacetylated pool of LC3 and shuttles it rapidly to the cytosol to
initiate autophagy (Huang et al, 2015). TP53INP2 is a positive regu-
lator of autophagy, and it interacts directly with the LIR sequence of
all Atg8 family members (Nowak et al, 2009; Mauvezin et al, 2010;
Sancho et al, 2012). We recently showed that TP53INP2 is also an
ubiquitin-binding protein, with a preference for mono- and K63-
linked ubiquitin chains (Sala et al, 2014).
Here 4, we identified an unexpected role of TP53INP2 in death
receptor signaling. We show that TP53INP2 sensitizes various
cancer cell lines to death receptor-induced apoptosis. We observed
that TP53INP2 increases the activation of caspase-8 by upregulating
its K63-ubiquitination levels in a TRAF6-dependent manner.
Furthermore, we demonstrate that TP53INP2 acts as a scaffold for
caspase-8 polyubiquitination by TRAF6. In addition, we show that
cancer cell lines with high protein levels of TP53INP2 respond better
to TRAIL-induced apoptosis than those with no or low amounts of
TP53INP2. This observation indicates that TP53INP2 might be a
potential biomarker for personalized TRAIL treatment in cancers
where caspase-8 protease activity is intact. Altogether, our findings
demonstrate that TP53INP2 acts as a switch at the level of caspase-8
activation, favoring death receptor-mediated apoptosis.
Results
TP53INP2 regulates death receptor-induced apoptosis
Several autophagic proteins participate in the cross-talk between
autophagy and apoptosis (Yousefi et al, 2006; Cho et al, 2009;
Laussmann et al, 2011; Huang et al, 2013; Strappazzon et al, 2016).
In this regard, we examined the role of TP53INP2 in apoptosis. We
overexpressed TP53INP2 in HeLa cells, which express undetectable
levels of this protein, and we induced cell death by various agents.
Surprisingly, TP53INP2 increased the sensitivity of cells to death
induced by ligands of death receptors more efficiently than to other
inducers (Fig 1A and Appendix Fig S1A). This observation
prompted us to explore the role of TP53INP2 in death receptor-
induced cell death. Using inhibitors of apoptosis (zVAD) and necro-
sis (necrostatin-1/Nec-1), annexin V staining [flow cytometry
measurement of phosphatidylserine exposure (PS)] and DEVDase
activity (indicative of caspase activity), we confirmed that TP53INP2
sensitizes cells to death receptor-induced apoptosis and not necrop-
tosis (Fig 1B and C, and Appendix Fig S1B). Furthermore, the acti-
vation of caspase-8 and caspase-3, and detection of the caspase-
generated 85 kDa fragment of PARP-1 were higher in cells express-
ing TP53INP2 and treated with a range of concentrations of FasL
and TRAIL (Fig 1D and E). TNFa induces apoptosis by activation of
the death receptor pathway by a process that is stimulated to cyclo-
heximide (Kreuz et al, 2001), and TNFa-induced apoptosis was
further augmented by TP53INP2 overexpression in HeLa cells
(Appendix Fig S1C and D). Similar results were obtained in
MDA231 and MCF7 cells treated with FasL (Appendix Fig S1E and
F). LC3-II protein levels were increased in TP53INP2-overexpressing
cells as previously described (Fig 1D and E; Sala et al, 2014). More-
over, time-course experiments showed that FasL-induced apoptosis
in TP53INP2-expressing cells occurs faster than in control cells. In
the former, apoptosis started around 4 h post-induction (Fig 1F). At
this time point, caspase-3 cleavage was detected and the levels of
TP53INP2 were the highest (Fig 1F), thereby supporting the notion
that TP53INP2 accumulates in the first 4 h of FasL treatment and
that TP53INP2 contributes to faster activation of apoptosis triggered
by death receptors. Similar results were obtained by time-course
experiment with TRAIL (Fig 1G). Since TP53INP2 is cleaved during
apoptosis and we detected a cleavage product of approximately
26 kDa (Fig 1D–G), we explored whether the sensitization of
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TP53INP2 to death receptor-induced apoptosis involves its cleavage
by caspases. To test this, we first mutated aspartate residues at
potential caspase cleavage sites (Fig 1H) to glutamate in order to
produce a caspase-noncleavable mutant form (TP53INP2 3DE).
Indeed, recombinant caspase-3 cleaved the wild-type TP53INP2 but
not the 3DE mutant (Appendix Fig S1G); however, the 3DE mutant
did not abolish the sensitization effect of TP53INP2 to FasL-induced
apoptosis (Fig 1I and J). This observation indicates that the mecha-
nism involved does not require the cleavage of TP53INP2 by
caspases.
In contrast, HeLa cells depleted of TP53INP2 by CRISPR tech-
nology were less sensitive to treatment with FasL or TRAIL
A B C
D E F
G H
JI
Figure 1. TP53INP2 sensitizes cells to death receptor-induced apoptosis.
A HeLa cells were treated with the indicated inducers of apoptosis for 24 h, and cell viability was assessed by annexin V and PI staining.
B The percentage of viable cells 24 h after FasL (50 ng/ml) and TRAIL (10 ng/ml) treatment in the absence or presence of zVAD-fmk (20 lM) or Nec-1 (30 lM).
C Quantification of DEVDase activity in HeLa cells after 16 h of FasL or 4 h of TRAIL treatment.
D, E HeLa cells were infected with adenovirus for LacZ or TP53INP2 and treated with different concentrations of FasL for 16 h (D) or TRAIL for 4 h (E). Cell lysates were
then subjected to Western blot analysis for various apoptotic and autophagic markers.
F Time-dependent cleavage of PARP-1, caspase-8, caspase-3, and TP53INP2 during FasL-induced apoptosis (50 ng/ml) in HeLa cells expressing LacZ or TP53INP2.
G Time-dependent cleavage of PARP-1, caspase-8, caspase-3, and TP53INP2 during TRAIL-induced apoptosis (50 ng/ml) in HeLa cells expressing LacZ or TP53INP2.
H Schematic presentation of caspase cleavage sites in human and mouse TP53INP2. LIR; LC3 interacting region.
I DEVDase activity quantification in lysates of HeLa cells expressing LacZ, wt TP53INP2 or TP53INP2 3DE mutant in control or FasL-treated cells (50 ng/ml; 16 h).
J HeLa cells were transduced with adenovirus for LacZ, wt TP53INP2 or 3DE mutant, and cell lysates were subjected to Western blot analysis with indicated
antibodies.
Data information: Data are given as mean  SEM and were analyzed by two-way Student’s t-test; n = three independent experiments, *P < 0.05.
Source data are available online for this figure.
C
O
L
O
R
ª 2019 The Authors The EMBO Journal e99300 | 2019 3 of 19
Saska Ivanova et al The EMBO Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
(Fig 2A–H). Thus, percentage of cell death was lower in
TP53INP2-deficient cells compared to wild-type cells upon FasL or
TRAIL (Fig 2B), and similarly, cleaved caspase-3 or PARP-1 was
reduced in TP53INP2-deficient cells treated with FasL or TRAIL
(Fig 2C–H).
Furthermore, we generated liver-specific TP53INP2 KO mice (L-
KO) by crossing Tp53inp2loxP/loxP mice (Sala et al, 2014) with mice
expressing Cre recombinase under the control of the albumin
promoter. TP53INP2 protein levels were undetectable in livers of L-
KO animals, and no changes in the protein levels in other tissues
were detected (Fig 2I; Appendix Fig S2A and B). L-KO male and
female mice showed normal body weight or blood glucose levels
(Appendix Fig S2C and D). Primary hepatocytes isolated from these
mice were less susceptible to FasL- and TNFa-induced apoptosis
than hepatocytes from control mice (Fig 2J and K, and Appendix Fig
S2E). Introducing TP53INP2 back to the L-KO hepatocytes by aden-
oviral infection restored the capacity of FasL or TNFa to induce
apoptosis, as reflected by increased amounts of cleaved PARP-1 and
cleaved caspase-3 (Appendix Fig S2E). Of note, overexpression of
TP53INP2 per se in control and L-KO hepatocytes was pro-apoptotic
(Appendix Fig S2E), thus making high amounts of TP53INP2 toxic
for the liver.
Taken together, our results show that TP53INP2 increases
susceptibility to death receptor-induced apoptosis and that it does
so upstream of caspase activation, i.e., before TP53INP2 is cleaved
by caspases.
A B C D
E
J K
F G H
I
Figure 2. Loss of TP53INP2 renders cells resistant to death receptor-induced apoptosis.
A Western blot analysis of TP53INP2 in wild-type (wt) HeLa and TP53INP2 CRISPR KD cells.
B Cell viability of HeLa wt and TP53INP2 KD cells after 24 h treatment with FasL (50 ng/ml) or TRAIL (10 ng/ml) measured as annexin V- and PI-negative cells.
C HeLa control cells and TP53INP2 CRISPR KD cells were treated with different concentrations of FasL for 16 h, and cell lysates were subjected to Western blot
analysis for PARP and caspase-3 cleavage.
D, E Quantification of protein levels of cleaved PARP (D) and cleaved caspase-3 (E) after FasL treatment.
F HeLa control cells and TP53INP2 CRISPR KD cells were treated with different concentrations of TRAIL for 4 h, and cell lysates were subjected to Western blot
analysis for PARP1, caspase-3, and caspase-8 cleavage.
G, H Quantification of protein levels of cleaved PARP (G) and cleaved caspase-3 (H) after TRAIL treatment.
I Detection of TP53INP2 protein levels in livers of control and L-TP53INP2 KO mice.
J Control and TP53INP2 KO hepatocytes were treated with FasL for 16 h, and levels of cleaved caspase-3 were detected by Western blot.
K Quantification of protein levels of cleaved caspase-3 after FasL treatment.
Data information: Data are given as mean  SEM and were analyzed by two-way Student’s t-test; n = three independent experiments, *P < 0.05.
Source data are available online for this figure.
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Loss-of-function of TP53INP2 protects livers from FasL-induced
apoptosis in vivo
We next tested whether TP53INP2 regulates death receptor-induced
apoptosis in vivo. Control and L-KO mice were injected intraperi-
toneally with PBS or FasL for 4 h. The cleavage product of PARP-1
and cleaved caspase-3 were detected in controls, but were absent or
present to a lesser extent in L-KO mice treated with FasL (Fig 3A
and B). Of note, protein levels of p62 were increased and LC3II
decreased in L-KO mice treated with PBS (Fig 3A), which is in keep-
ing with prior observations in TP53INP2-deficient skeletal muscle
(Sala et al, 2014). In addition, immunohistochemical staining
showed more cleaved caspase-3 positive cells in control livers
treated with FasL than in L-KO livers (Fig 3C and D). Analysis of
TUNEL-positive cells further confirmed more apoptotic cells in
control livers treated with FasL than in L-KO livers (Fig 3E and F).
Given that caspase-8 activation is not sufficient to directly cleave
caspase-3 in liver cells and the signal is amplified through mitochon-
dria, we also checked by immunofluorescence the release of cyto-
chrome c from mitochondria. TOM20 was used as marker of
mitochondria. As expected, cytochrome c colocalized with TOM20
in PBS-treated livers of control and L-KO mice (Fig 3G and H; and
Appendix Fig S3A). However, in FasL-treated livers of control
animals, cytochrome c did not completely colocalize with this
marker, indicating the release of cytochrome c from mitochondria
(Fig 3G and H; and Appendix Fig S3A) and apoptosome formation,
leading to the activation of executioner caspases (i.e., caspase-3). In
contrast, colocalization of TOM20 and cytochrome c was detected in
FasL-treated L-KO mice (Fig 3G and H, and Appendix Fig S3A).
To determine whether TP53INP2 deficiency has an impact on
death receptor independent pathway, control and KD HeLa cells
were treated with agents that induce intrinsic cell death such as
doxorubicin, cisplatin, or actinomycin D. These agents reduced cell
viability in a time-dependent manner (Fig 4A). However, only upon
actinomycin D treatment, a significant increase in viability was
detected in TP53INP2-deficient cells (Fig 4A). DEVDase activity was
similarly induced in control and TP53INP2-deficient cells upon treat-
ment with doxorubicin, cisplatin, or actinomycin D (Fig 4B), and
cleaved PARP-1 was lower in TP53INP2 KD cells compared to
controls upon cisplatin but not after doxorubicin and actinomycin D
treatment (Fig 4D). Next, control and TP53INP2 L-KO mice were
treated with doxorubicin or cisplatin for 48 h. No differences
between control and L-KO groups were visualized when immunode-
tecting either cleaved caspase-3 (Fig 4E and F) or TUNEL-positive
cells upon treatment with doxorubicin (Fig 4E–H). In contrast,
cisplatin administration caused reduction in cleaved caspase-3 or
TUNEL-positive cells in livers from L-KO mice compared with
control mice (Fig 4E–H). Taken together, our data indicate that
TP53INP2 regulates the cell death receptor pathway as well as
some, but not all, of the intrinsic apoptotic pathways in mouse liver.
Regulation of death-receptor signaling by TP53INP2 does not
require canonical autophagy
Given that autophagy is involved in the regulation of caspase-8 acti-
vation (Bell et al, 2008; Pan et al, 2011; Huang et al, 2013), we first
studied whether TP53INP2 sensitization to death receptor-induced
apoptosis depends on autophagy. ATG5 was downregulated in HeLa
cells by shRNA (Appendix Fig S4A), and apoptosis was induced
with FasL. ATG5 deficiency did not abrogate DEVDase activity and
apoptosis (Appendix Fig S4B), thereby indicating that canonical
autophagy does not participate in the mechanism by which
TP53INP2 sensitizes cells to FasL-induced apoptosis. We further
confirmed this observation by generating ATG7 KO cells with
CRISPR technology, and we obtained the same results as with the
ATG5 KD model (Appendix Fig S4C–G). In addition, inhibition of
autophagy with bafilomycin A1 (Baf A1) or wortmannin (Wort) did
not rescue the enhanced FasL-induced apoptosis in TP53INP2-
expressing cells (Appendix Fig S4H). All together, these data show
that TP53INP2 sensitization to FasL does not require autophagy or
intracellular DISC formation.
TP53INP2 interacts with and increases the levels of
ubiquitinated caspase-8
An autophagy cargo protein, p62, has been shown to directly acti-
vate caspase-8 by aggregating ubiquitinated caspase-8 (Jin et al,
2009). TP53INP2 overexpression upregulates p62 (Sala et al, 2014);
thus, we addressed whether TP53INP2 function in death receptor
signaling is dependent on p62. The downregulation of p62 did not
rescue FasL-induced cell death in TP53INP2-expressing cells, even
though there was slightly less apoptosis in p62 knock-down cells
(Appendix Fig S4I and J). On the basis of these observations, we
then explored whether TP53INP2 participates directly in caspase-8
activation. Caspase-8-deficient cells (Appendix Fig S4K) showed
reduced FasL-induced apoptosis in control and TP53INP2-expres-
sing cells (Appendix Fig S4L and M). Surprisingly, caspase-8 knock-
down cells tolerated higher protein levels of TP53INP2 than the
scrambled cells (Appendix Fig S4M), thereby further corroborating
our hypothesis that TP53INP2 acts directly through caspase-8. In
order to prove this, we examined whether TP53INP2 aggregated
caspase-8 in a similar way as p62, especially since both proteins
bind ubiquitin and are aggregation-prone. TP53INP2 aggregated
caspase-8 to almost the same extent as p62 (Fig 5A and B);
however, caspase-8 dots in TP53INP2-overexpressing cells were
much smaller than those in p62-overexpressing ones. These obser-
vations suggest that p62 has higher affinity to ubiquitinated
caspase-8 than TP53INP2 and/or that TP53INP2 acts upstream of
the aggregation of ubiquitinated caspase-8. To confirm that
TP53INP2 has a direct effect on caspase-8 activation, we next exam-
ined whether the two proteins colocalize. Caspase-8 and TP53INP2
colocalized in a dot-like manner, but again to a lesser extent than
p62 (Appendix Fig S4N). Since we previously showed that
TP53INP2 dislocates p62 from LC3 in autophagy (Sala et al, 2014),
a process in which the two proteins compete for the same binding
site, we examined whether they also compete for the same binding
sites in caspase-8 or ubiquitinated caspase-8. To test this notion, we
co-expressed p62, TP53INP2, and caspase-8 and analyzed their
localization. All three proteins colocalized in large aggregate-like
dots (Appendix Fig S4O), thereby suggesting that they are in the
same pathway and that p62 and TP53INP2 do not exclude each
other from caspase-8-positive dots; i.e., TP53INP2 and p62 do not
bind to the same binding sites in (ubiquitinated) caspase-8. We con-
firmed this also with endogenous proteins in Snu449 cells, in which
TP53INP2, p62, and caspase-8 completely colocalized when
caspase-8 was aggregated upon TRAIL treatment (Fig 5C and D).
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Figure 3. TP53INP2 deficiency protects livers from FasL-induced apoptosis.
A Control and TP53INP2 L-KO animals were injected with PBS or FasL i.p. for 4 h. Whole liver lysates were subjected to immunodetection of the indicated apoptotic
and autophagic markers.
B Quantification of Western blot of cleaved caspase-3 and PARP. Data are presented as mean  SEM of four samples.
C Cleaved caspase-3 immunohistochemistry staining of livers from control and TP53INP2 L-KO mice treated with PBS or FasL (Scale bar, 100 lm).
D Quantification of cleaved caspase-3 immunohistochemistry staining. Data are presented as mean  SEM of nine different fields (per mice) where in each field more
than 200 cells were counted.
E TUNEL immunohistochemistry staining of livers from control and TP53INP2 L-KO mice treated with PBS or FasL (Scale bar, 100 lm).
F Quantification of TUNEL immunohistochemistry staining. Data are presented as mean  SEM of more than 1,500 cells counted per mice (four mice in each
experimental group).
G TOM20 (red) and cytochrome C (green) immunohistofluorescence staining of livers from control and TP53INP2 L-KO mice (Scale bar, 25 lm).
H Quantification of cells with disperse cytochrome c staining. Data are presented as mean  SEM of more than 300 cells counted per each experimental group.
Data information: Two-way Student’s t-test was performed, *P < 0.05.
Source data are available online for this figure.
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Figure 4. TP53INP2 differentially sensitizes to intrinsic apoptotic inducers.
A, B Viability (A) and DEVDase activity (B) of HeLa control and TP53INP2 KD cells treated with doxorubicin, cisplatin, and actinomycin D. Data are presented as
mean  SEM of n = 4–8 of independent experiments in panel A and three in panel B.
C Immunodetection of cleaved PARP in control and TP53INP2 KD cells after treatment with doxorubicin, cisplatin, and actinomycin D.
D Quantification of protein levels of cleaved PARP. Data are presented as mean  SEM of at least three independent experiments.
E Cleaved caspase-3 immunohistochemistry staining of livers from control and TP53INP2 L-KO mice treated with PBS, doxorubicin, or cisplatin (Scale bar, 100 lm).
F Quantification of cleaved caspase-3 immunohistochemistry staining. Data are presented as mean  SEM of nine different fields (per mice) where in each field
more than 200 cells were counted.
G TUNEL immunohistochemistry staining of livers from control and TP53INP2 L-KO mice treated with PBS, doxorubicin, or cisplatin (Scale bar, 100 lm).
H Quantification of TUNEL immunohistochemistry staining. Data are presented as mean  SEM of more than 1,500 cells counted per mice (four mice in each
experimental group).
Data information: Two-way Student’s t-test was performed, *P < 0.05.
Source data are available online for this figure.
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Figure 5. TP53INP2 interacts with caspase-8 and regulates its ubiquitination levels.
A HeLa cells were transfected with xpress-casp-8-NCC alone or together with TP53INP2 or p62. Casp-8 localization and dot-like structures were detected with xpress
antibody (Scale bar, 10 lm).
B Quantification of caspase-8 dots in immunofluorescence experiment. Data are presented as mean  SEM of 25 cells per experimental group.
C Immunofluorescence colocalization analysis of caspase-8 with TP53INP2 and p62 in Snu449 cells in control or TRAIL (250 ng/ml) treated cells for 30 min (Scale bars,
10 lm).
D Quantification of the colocalization. Data are presented as mean  SEM of 25 cells per experimental group.
E HEK293T cells were transfected with xpress-casp-8-NCC and FLAG-TP53INP2, and 24 h later, cell lysates were pulled down with FLAG resin. IPs and inputs were
afterward immunodetected with xpress and TP53INP2 antibody.
F HEK293T cells were transfected with wt FLAG-casp-8 or FLAG-casp-8-Ub6 or FLAG-casp-8-Ub9 with or without TP53INP2 in the presence of 20 lM z-VAD-fmk. Pull-
down assays were done with FLAG resin. IPs and inputs were immunodetected with FLAG or TP53INP2 antibodies.
G Pull-down assay of recombinant pro-caspase-8 and TP53INP2.
H HEK293T cells were transfected with xpress-casp-8-NCC, His-Ub, and TP53INP2 in the presence or absence of 20 lM z-VAD-fmk. Denaturing pull-down assays were
done with His resin. IPs and inputs were immunodetected with the indicated antibodies.
I Denaturing pull-down assays of HEK293T cells transfected with indicated plasmids. IPs and inputs were subjected to immunodetection with xpress, casp-8, and
TP53INP2 antibodies. The amount of ubiquitinated casp-8 was quantified with Fiji software.
Data information: Two-way Student’s t-test was performed, *P < 0.05.
Source data are available online for this figure.
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Surprisingly, TP53INP2 is not mainly nuclear in Snu449 cells
(Fig 5C). This is coherent with the fact that caspase-8 activation in
death receptor-induced apoptosis is cytosolic. We further analyzed
whether the cellular localization of TP53INP2 in HeLa cells is coher-
ent with the cytosolic aggregation and activation of caspase-8.
Immunolocalization and subcellular fractionation assays revealed
that TP53INP2 was mainly nuclear in HeLa cells at all times after
TRAIL treatment, but a significant proportion of TP53INP2 was also
cytosolic, and therefore available for interaction with caspase-8
(Appendix Fig S5A–D, Movie EV1).
In order to further confirm the interaction, we performed co-
immunoprecipitation experiments of caspase-8 and TP53INP2. We
pulled down caspase-8 with TP53INP2 (Fig 5E), and this interaction
was not due to the ubiquitination of TP53INP2, since we obtained
the same result with a TP53INP2 mutant that cannot be ubiquiti-
nated (3KR, Appendix Fig S4P). Moreover, we pulled down
TP53INP2 with wild-type caspase-8 and to a higher extent with
chimeric proteins of caspase-8 fused to 6 or 9 ubiquitins (Fig 5F). In
5 this experiment, we added zVAD-fmk to the cells due to high levels
of apoptosis, especially in those transfected with caspase-8-Ub6 or
caspase-8-Ub9. Altogether, our pull-down assays showed that
TP53INP2 and caspase-8 interact and that this interaction is stronger
in the presence of ubiquitin(s). We can rule out this interaction
being due exclusively to the cleavage of TP53INP2 by caspase-8
since we also detected it in the presence of zVAD-fmk, an inhibitor
of caspases that irreversibly binds to the catalytic site of caspase
proteases.
Our results indicate that TP53INP2 binds to caspase-8 and/or
ubiquitinated caspase-8. To discriminate between these two possi-
bilities, we tried to identify the ubiquitin-binding motifs in
TP53INP2. We split TP53INP2 into two halves and used these
constructs for the pull-down assays. The N-terminal half of
TP53INP2 retained capacity to interact with ubiquitin/ubiquitinated
proteins, while interaction with the C-terminal half was almost
completely abolished (Appendix Fig S6A). We excluded the possibil-
ity of the N-terminal part being ubiquitinated as all three Lys resi-
dues in the protein are at the C-terminal. We checked the TP53INP2
sequence and identified a potential ubiquitin-interacting motif (UIM;
Appendix Fig S6B). Mutation of the key residues in the UIM motif
(Appendix Fig S4B) caused a 20% decrease in the interaction of
TP53INP2 ALA mutant with ubiquitin (Appendix Fig S6C and D).
This observation suggests that besides the potential UIM motif
TP53INP2 has additional ubiquitin-binding motifs/domains. Since
we could not make a mutant of TP53INP2 lacking the capacity to
bind ubiquitin, we performed experiments with recombinant
proteins. As seen in Fig 5G, we pulled down TP53INP2 with
caspase-8 in the absence of ubiquitin (even when caspase-8 was
aggregating), supporting the view that TP53INP2 interacts directly
with caspase-8.
We next tested whether TP53INP2 acts upstream of caspase-8
ubiquitination, i.e., whether it participates in the regulation of
caspase-8 ubiquitination. We performed denaturing pull-down
assays with His-Ub and caspase-8 in the presence or absence of
TP53INP2. The addition of TP53INP2 upregulated the levels of ubiq-
uitinated caspase-8, and caspase-8 and TP53INP2 were cleaved,
thereby confirming faster activation of caspase-8 in the presence of
TP53INP2 (Fig 5H). In order to fully appreciate the difference in the
degree of caspase-8 ubiquitination, experiments were performed by
pre-treating the cells with zVAD-fmk. Again, and to a much higher
extent, TP53INP2 upregulated the levels of ubiquitinated caspase-8
compared with the sample without TP53INP2 (Fig 5H). Several
studies have reported that ubiquitin chains added to caspase-8 can
be K48 or K63 (He et al, 2006; Jin et al, 2009; Gonzalvez et al,
2012; Li et al, 2013). Ubiquitin K48 chains mark caspase-8 for
degradation, while ubiquitin K63 can enhance or block the activa-
tion of the caspase-8, depending on which Lys residue is ubiquiti-
nated. To determine the chains that are preferentially added to
caspase-8 in the presence of TP53INP2, we used mutants of ubiqui-
tin that can make only K48 or K63 chains. As expected, mainly
because TP53INP2 enhances apoptosis, we detected an increase in
the K63 ubiquitination of caspase-8 in the presence of TP53INP2
(Fig 5I), precisely the type of ubiquitination that favors caspase-8
activation. Collectively, our data show that TP53INP2 colocalizes
and interacts with caspase-8. Moreover, they reveal that TP53INP2
promotes caspase-8 ubiquitination with K63 ubiquitin chains.
TP53INP2 sensitization to death receptor-induced apoptosis is
dependent on TRAF6
TP53INP2 is not an E3 ubiquitin ligase, but it may act as a scaffold,
bringing together several components of the same complex for a
more efficient function of the signaling hub. To determine the E3
ubiquitin ligase responsible for the enhanced ubiquitination of
caspase-8 in the presence of TP53INP2, we first analyzed cullin-3,
which ubiquitinates caspase-8 with K63 chains in death receptor-
induced apoptosis (Jin et al, 2009). We did not detect any interac-
tion between TP53INP2 and cullin-3 (Appendix Fig S7A). Further-
more, we repressed cullin-3 expression (Appendix Fig S7B) and
induced apoptosis with FasL in control and TP53INP2-expressing
cells. No differences in the levels of cleaved caspase-3 were detected
in wild-type or CUL3-deficient cells upon TP53INP2 expression
(Appendix Fig S7C). These observations thus exclude this E3 ubiqui-
tin ligase as being responsible for enhanced caspase-8 ubiquitination
in the presence of TP53INP2.
Two more E3 ubiquitin ligases, TRAF6 and HECTD3, have been
reported to add K63 chains to caspase-8 during death receptor-
induced apoptosis (He et al, 2006; Li et al, 2013). HECTD3 K63-
linked polyubiquitination of caspase-8 inhibits its activation, so we
focused on TRAF6. TRAF6 was knocked out by CRISPR technology
(Fig 6A). The absence of TRAF6 alone decreased FasL- and TRAIL-
induced apoptotic cell death compared to control cells (Fig 6A). The
same was seen in MDA231 TRAF6 KO cells (Appendix Fig S8A). In
addition, TRAF6 deficiency reduced FasL- and TRAIL-induced
caspase activity, the levels of cleaved caspase-3 and cleaved PARP-
1, and percentage of cell death in TP53INP2-expressing cells
(Fig 6B–H, and Appendix Fig S8B). Furthermore, we obtained simi-
lar results in TRAF6 KO MEF cells (Appendix Fig S8C and D).
Moreover, TP53INP2 immunoprecipitated with TRAF6 in basal
conditions and to a greater extent after a 20 min treatment of the
cells with FasL (Fig 6I). However, this interaction appeared to be
transient, since the amount of TP53INP2 immunoprecipitated
dropped after 1 h of FasL treatment, or, on the other hand, caspase-
8 was already activated in TRAF6- and TP53INP2-overexpressing
cells and started cleaving TP53INP2, which might explain the
decrease in the levels of TP53INP2 in the extracts (inputs in Fig 6I).
In addition, the interaction of TRAF6 and TP53INP2 did not depend
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on the ubiquitination of TP53INP2 by TRAF6, since the TP53INP2
3KR mutant interacted with TRAF6 to same extent (Appendix Fig
S8E).
We mapped a TRAF6-interacting motif (TIM; Ye et al, 2002) in
the N-terminal part of TP53INP2 (Fig 6J). We mutated the two key
residues in the TIM, generating the TP53INP2 TIM mutant (Fig 6J).
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The mutation of TIM in TP53INP2 reduced the binding to TRAF6 by
about 50% compared to the wild type (Fig 6K). Mutations of
TP53INP2 in the N-terminal might alter its exit from the nucleus;
however, we proved that this was not the case with the TIM mutant,
in contrast to the LIR mutant, which was unable to leave the
nucleus (Appendix Fig S8F). Moreover, overexpression of the TIM
and LIR mutant decreased the levels of FasL-induced apoptosis
compared to the wild-type TP53INP2 (Appendix Fig S8G), thereby
suggesting that the sensitization of TP53INP2 to FasL apoptosis
relies on its binding to TRAF6 and also on its ability to exit the
nucleus. In addition, we co-immunoprecipitated endogenous
caspase-8 with TRAF6. The interaction was stronger in the presence
of TP53INP2 (Fig 6L), thus indicating that caspase-8, TRAF6, and
TP53INP2 are in the same complex. We could also co-immunopreci-
pitate endogenous TRAF6 and TP53INP2 with endogenous caspase-
8 in HeLa cells stably expressing TP53INP2 (Fig 6M). Catalytically
inactive TRAF6 (C70A) did not pull down the endogenous caspase-
8. Also, the amount of TP53INP2 was reduced dramatically
(Fig 6N), implying that the strength of the caspase-8/TRAF6/
TP53INP2 complex depends on the ubiquitination activity of TRAF6.
Since the TP53INP2 TIM mutant and the TRAF6 C70A mutant
reduced the binding of TRAF6 and TP53INP2 to the same extent, we
speculated that the remaining binding between the two proteins (in
Fig 6N) is not due to an additional TRAF6 binding site in TP53INP2
but to the binding of TP53INP2 to ubiquitinated TRAF6 itself or to
other ubiquitinated components of the complex. Indeed, expression
of the TP53INP2 TIM and TRAF6 C70A mutants abolished the inter-
action between the two proteins (Fig 6N). The direct interaction
between the two proteins (TRAF6 and TP53INP2) was also seen in
in vitro pull-down of recombinant proteins (Fig 6O). To confirm that
TP53INP2 upregulates caspase-8 ubiquitination in the presence of
TRAF6, we performed an in vitro ubiquitination assay. TRAF6 alone
ubiquitinated caspase-8. However, the addition of TP53INP2 further
increased the ubiquitination of caspase-8 (Fig 6P).
Taken together, our results support the notion that TP53INP2
acts as a scaffold for caspase-8 ubiquitination by TRAF6.
Protein levels of TP53INP2 correlate with sensitivity of cancer
cell lines to TRAIL treatment
TRAIL kills cancer cells selectively without major damage to normal
cells. Therefore, this specific apoptotic pathway has been exten-
sively studied for possible clinical applications (Naoum et al, 2017).
However, initial enthusiasm was back-fired by unsuccessful TRAIL
pre-clinical/clinical trials that highlighted the need for optimized
TRAIL antagonists and for strategies to optimize the selection of
patients who would most benefit from TRAIL treatment (i.e.,
through biomarkers; de Miguel et al, 2016; Naoum et al, 2017; von
Karstedt et al, 2017). In line with this notion, our results suggest
that TP53INP2 may serve as a potential biomarker for the selection
of patients for TRAIL treatment. In order to further explore this
possibility, we first screened several breast cancer cell lines for
protein levels of TP53INP2 and then determined the percentage of
cells undergoing apoptosis upon TRAIL treatment. The 6cell lines dif-
fered in their protein levels of TP53INP2: those with highest levels
being BT20, whereas MCF7 and BT474 showed no TP53INP2 or
undetectable levels (Fig 7A). As expected, BT20 cells were the most
sensitive to TRAIL treatment, whereas the cell lines with no or less
TP53INP2 did not undergo apoptosis (Fig 7B, and Appendix Fig S9A
and C). Moreover, there was a positive correlation (r = 0.84)
between the protein levels of TP53INP2 and susceptibility to apopto-
sis (Fig 7C). We did the same set of experiments in various liver
cancer cell lines and obtained the same results; i.e., Snu449 cells
had the highest levels of TP53INP2 and responded to TRAIL
◀ Figure 6. TRAF6 is indispensable for TP53INP2 function in death receptor-induced apoptosis.A Western blot analysis of TRAF6 and viability assay in wt HeLa cells and TRAF6 CRISPR KO cells. Data are presented as mean  SEM of five independent
experiments.
B HeLa wt and TRAF6 KO cells expressing LacZ or TP53INP2 were treated with 50 ng/ml FasL for 16 h, and whole lysates were analyzed by Western blot against
PARP-1, caspase-8, and caspase-3 antibodies.
C, D Quantification of protein levels of cleaved PARP and caspase-3. Data are presented as mean  SEM of three independent experiments.
E HeLa wt and TRAF6 KO cells expressing LacZ or TP53INP2 were treated with 25 ng/ml TRAIL for 4 h, and whole lysates were analyzed by Western blot against
PARP-1, caspase-8, and caspase-3 antibodies.
F, G Quantification of protein levels of cleaved PARP and caspase-3. Data are presented as mean  SEM of three independent experiments.
H Viability assay of HeLa wt and TRAF6 KO cells expressing LacZ or TP53INP2 and treated with 50 ng/ml FasL or 10 ng/ml TRAIL for 24 h. Data are presented as
mean  SEM of five to eight independent experiments.
I HEK293T cells expressing FLAG-TRAF6 and/or TP53INP2 were left untreated or treated with FasL (100 ng/ml) for the indicated times and then immunoprecipitated
with FLAG resin. Immunocomplexes were subjected to Western blot analysis with anti-FLAG and anti-TP53INP2 antibodies.
J Schematic presentation of the consensus TRAF6 interaction motif (TIM) in TP53INP2 protein and the amino acids mutated in a TP53INP2 TIM mutant.
K HEK293T cells expressing FLAG-TRAF6, wt TP53INP2, and TIM mutant were immunoprecipitated with FLAG resin, and immunocomplexes were analyzed by Western
blot with anti-FLAG and anti-TP53INP2 antibody. The amount of TP53INP2 precipitated with TRAF6 was quantified with Fiji software. Data are presented as
mean  SEM of three independent experiments.
L HEK293T cells expressing FLAG-TRAF6 and TP53INP2 were immunoprecipitated with FLAG resin, and immunocomplexes were subjected to Western blot analysis
with anti-FLAG, anti-TP53INP2, and anti-caspase-8 antibody. Note that we were able to immunoprecipitate endogenous caspase-8 in the same complex with
TRAF6 and TP53INP2.
M HeLa cells stably overexpressing TP53INP2 were left untreated or treated with 100 ng/ml TRAIL for 30 min and subjected to immunoprecipitation with caspase-8
antibody. Immunocomplexes were subjected to Western blot analysis with anti-TRAF6, anti-TP53INP2, and anti-caspase-8 antibody.
N The same as in (L), except that we also expressed FLAG-TRAF6 C70A and/or TP53INP3 TIM mutant.
O Pull-down assay of recombinant GST-TRAF6 and FLAG-TP53INP2 proteins using FLAG resin and Western blot analysis of immunocomplexes with anti-GST and anti-
TP53INP2 antibodies.
P In vitro ubiquitination assay with immunoprecipitated xpress-casp-8-NCC, FLAG-TRAF6, and TP53INP2.
Data information: Two-way Student’s t-test was performed, *P < 0.05.
Source data are available online for this figure.
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treatment, while those with no or almost undetectable levels of
TP53INP2 did not (Fig 7D and E; Appendix Fig S9B and D). In the
case of liver cancer cell lines, we also detected a positive correlation
between TP53INP2 and percentage of dying cells (r = 0.87; Fig 7F).
The expression of Bcl-2 homologues did not correlate with
TP53INP2 expression in the different cells studied (Appendix Fig
S9E and F). In addition, the differences observed in the Bcl-2 homo-
logues between different cell lines do not explain the differences
seen in susceptibility to TRAIL treatment (Appendix Fig S9E and F).
Moreover, downregulation of TP53INP2 expression in MDA231 and
Snu449 cells reduced the response to TRAIL treatment (Fig 7G–J).
On the contrary, the overexpression of TP53INP2 in different breast
and liver cancer cell lines with no or low levels of TP53INP2 sensi-
tized them to TRAIL-induced apoptosis (Appendix Fig S9G–J).
Collectively, our results suggest that cancer cell lines that express
high levels of TP53INP2 will respond favorably to TRAIL-induced
apoptosis and that TP53INP2 might be a good biomarker of respon-
siveness to TRAIL treatment.
Discussion
The engagement of death ligands with death receptors can trigger
three signaling cascades, i.e., apoptosis, necroptosis, or the NF-kB
pathway (Tummers & Green, 2017), depending on the signaling
complexes being formed downstream of death receptors and the
proteins expressed in a given cell. Recently, several new compo-
nents in this pathway have been reported (Jin et al, 2009; Murphy
et al, 2013; Lu et al, 2014; de Miguel et al, 2016), thus increasing
their complexity and shedding light on how the same event can give
such divergent outcomes. In the context of cancer, it is important to
understand how we can manipulate the death receptor pathway and
switch between outcomes, in this case preferentially to apoptosis.
Here, we have shown that TP53INP2 is one of such switches, favor-
ing apoptosis in cells that have a sufficient amount of TP53INP2.
Increasing the amount of TP53INP2 in cells depleted or deficient in
this protein by adenoviral or other means of manipulating its
expression would sensitize them to TRAIL. It is important to state
that TP53INP2 exerts this role in cells where active caspase-8 can
induce apoptosis. In cells with low caspase-8 expression, the apop-
totic effect of TP53INP2 is reduced. Surprisingly, in caspase-8
knock-down cells, the protein levels of TP53INP2 tolerated are
much higher than in wild-type cells, thus suggesting that caspase-8
regulates TP53INP2 protein levels or that cells with a high amount
of both caspase-8 and TP53INP2 undergo apoptosis spontaneously.
Indeed, we observed spontaneous apoptosis of TP53INP2-overex-
pressing primary hepatocytes. This finding would indicate that high
protein levels of TP53INP2 are toxic.
TP53INP2 is an intrinsically disordered protein, which makes dif-
ficult any prediction of protein-protein interactions. However, it is a
scaffold, thus explaining its role in mediating protein-protein inter-
actions, most probably through short binding motifs like in the case
of LIR (LC3 interacting region; Sancho et al, 2012) or hormone
nuclear binding motif (Baumgartner et al, 2007), which are just few
amino acids long and are sufficient for efficient interaction and scaf-
folding function in signaling hubs. Here, we identified a TIM (Ye
et al, 2002) around 20 amino acids preceding LIR motif in
TP53INP2. The binding of TRAF6 would probably sterically impede
the interaction with LC3 at the same time, thus explaining why we
do not see a major effect of autophagy on TP53INP2 sensitization to
death receptor signaling. In contrast, we were unable to identify all
the ubiquitin binding sites in TP53INP2. Since TP53INP2 is an acidic
protein, additional binding to ubiquitin in the TP53INP UIM mutant
might be due to the interaction of negatively charged amino acids of
TP53INP2 with positively charged surface patches in ubiquitin,
thereby accommodating the secondary structure of TP53INP2 upon
binding, a phenomenon known to occur when intrinsically
disordered proteins bind to their cognitive interactors.
Our data demonstrate that TP53INP2 activates caspase-8 by
promoting its ubiquitination by TRAF6 and, in consequence, it shifts
the response toward apoptotic cell death. TP53INP2 acts as a signal-
ing adaptor, bringing together crucial components of the signaling
pathway, namely TRAF6, caspase-8, and ubiquitin (Fig 7A–C). The
TIM of TP53INP2 is postulated to bind to the canonical adaptor
binding groove of the TRAF_C domain of TRAF6, a domain that
normally recognizes upstream regulators of TRAF6 (Ye et al, 2002;
Shi et al, 2015). The N-terminal RING finger domain of TRAF6 binds
to the E2 Ubc13 displaying E3 ubiquitin ligase activity and mediat-
ing K63-linked ubiquitination of caspase-8, thus modulating activa-
tion of apoptosis (Fig 7B and C; Wooff et al, 2004). We propose that
TP53INP2, like p62, binds to ubiquitinated caspase-8, probably
before the caspase is fully activated. Activated caspase-8 can cleave
TP53INP2 at the LIR motif, thus separating the part encompassing
the TIM from the rest of the protein, including the UIM region. This
cleavage would inactivate TP53INP2 function in death receptor-
induced apoptosis, but also in autophagy, since it cuts off the LIR
region from the major part of the protein. In contrast to our previous
data on autophagy, where TP53INP2 and p62 are mutually exclusive
in binding to Atg8 homologues (Sala et al, 2014), both can bind to
ubiquitinated caspase-8 and promote its activation. In addition, p62
also binds to TRAF6 and, like TP53INP2, participates in determining
TRAF6 substrates (Jadhav et al, 2011). It will be interesting to deter-
mine the extent to which the substrates are shared between the
TRAF6/p62 and TRAF6/TP53INP2 complexes and to identify those
that are unique to each complex. Caspase-8 may not be common to
the two scaffold proteins, since it does not have the TRAF6/p62
ubiquitination consensus site (Jadhav et al, 2011), and repression of
p62 does not rescue TP53INP2 sensitization to death receptor-
induced apoptosis (Appendix Fig S3F and G). Our data, in addition
to other studies (Jin et al, 2009), indicate that p62 interacts with
ubiquitinated caspase-8 and facilitates its aggregation and full acti-
vation. Since both p62 and TP53INP2 are involved in differentiation
(Linares et al, 2011; McManus & Roux, 2012; Li et al, 2014;
Sugiyama et al, 2017), apoptosis (Jin et al, 2009; Moscat & Diaz-
Meco, 2009; Bhattacharya et al, 2015), nuclear hormone receptor
signaling (Baumgartner et al, 2007; Duran et al, 2016), diabetes
(Sala et al, 2014; Kruse et al, 2015; Long et al, 2017), and autop-
hagy (Pankiv et al, 2007; Moscat & Diaz-Meco, 2009; Nowak et al,
2009; Mauvezin et al, 2010; Sancho et al, 2012), further studies are
needed to unravel how they interplay/overlap in these pathways.
Along the same line, TRAF6 has been implicated in multiple signal-
ing pathways, such as autophagy, development, and immunity
(Linares et al, 2015; Walsh et al, 2015). We previously showed that
TP53INP2 modulates skeletal muscle mass by regulating autophagy
(Sala et al, 2014), and the same has been shown for TRAF6 (Paul &
Kumar, 2011). These observations thus suggest that these two
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proteins work together to regulate skeletal muscle mass. In addition,
TRAF6 has a regulatory role in amino acid starvation and mitophagy
(Murata et al, 2013; Linares et al, 2015), raising the question as to
whether TP53INP2 also has an adaptor role for TRAF6 in these two
processes or more in general, which are the pathways that TRAF6 is
involved in and might be modulated by TP53INP2.
As mentioned, TRAIL induces selective apoptosis in cancer cells
(Ashkenazi et al, 1999; Walczak et al, 1999); however, this feature
A
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Figure 7. TP53INP2 is a molecular biomarker for TRAIL responsive tumor cell lines.
A Set of breast cancer cell lines analyzed by Western blot for the protein levels of TP53INP2 and other components of the TRAIL signaling pathway.
B Viability of breast cancer cell lines after 24 h with 10 or 25 ng/ml of TRAIL was measured by annexin V and PI using flow cytometer. Cells that were annexin V- and
PI-negative were considered viable. Data are presented as mean  SEM of three independent experiments.
C Correlation plot of TP53INP2 protein levels and cell death in breast cancer cell lines; r = Pearson’s coefficient.
D Set of liver cancer cell lines analyzed by Western blot for the protein levels of TP53INP2 and other components of the TRAIL signaling pathway.
E Viability of liver cancer cell lines after 24 h with 10 or 25 ng/ml of TRAIL was measured by annexin V and PI using a flow cytometer. Cells that were annexin V- and
PI-negative were considered viable. Data are presented as mean  SEM of three or four independent experiments.
F Correlation plot of TP53INP2 protein levels and cell death in liver cancer cell lines; r = Pearson’s coefficient.
G Western blot of TP53INP2 in MDA231 wt and CRISPR KD cells.
H Cell viability of MDA231 wt and TP53INP2 KD cells after 25 ng/ml TRAIL treatment. Data are presented as mean  SEM of three or four independent experiments.
I Western blot of TP53INP2 in Snu449 wt and CRISPR KD cells.
J Cell viability of Snu449 wt and TP53INP2 KD cells after 25 ng/ml TRAIL treatment. Data are presented as mean  SEM of four or five independent experiments.
Data information: Two-way Student’s t-test was performed; *P < 0.05, **P < 0.01, ***P < 0.001.
Source data are available online for this figure.
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Figure 8. Model of TP53INP2 function in death receptor-induced apoptosis.
A Schematic presentation of TP53INP2 function in death receptor signaling. Upon receiving an upstream signal, the DISC complex is formed, where caspase-8 is
recruited. TP53INP2 facilitates TRAF6 and caspase-8 complex and subsequent caspase-8 ubiquitination and activation.
B, C Proposed molecular mechanism of TP53INP2 in the ubiquitination of caspase-8 by TRAF6. E2 Ubc13 binds to the N-terminal RING and first ZZ domain of TRAF6,
while TP53INP2 binds to the adaptor groove of the TRAF_C domain of TRAF6. In addition, TP53INP2 binds caspase-8 (B) and/or ubiquitinated caspase-8 (C), thus
bringing caspase-8 and Ubc13 closer together for a more efficient ubiquitin transfer from Ubc13 to caspase-8. Since we could not make a mutant of TP53INP2 that
cannot bind to ubiquitin, we cannot clearly discriminate between the two options. Our data indicate that TP53INP2 can bind to both forms of caspase-8 (non-
ubiquitinated and ubiquitinated). However, binding is more efficient if caspase-8 is ubiquitinated, suggesting that TP53INP2 facilitates polyubiquitination of
caspase-8 (C).
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has not brought any benefit to cancer patients so far. There is a need
for optimized TRAIL antagonists and strategies to tackle the resis-
tance of tumors to TRAIL monotherapy. Furthermore, there is also a
lack of biomarkers that can effectively identify patients likely to
respond favorably to TRAIL-based therapy (Lemke et al, 2014b). To
date, only one potential biomarker has been discovered. In this
regard, CDK9 inhibition leads to the downregulation of two anti-
apoptotic proteins, namely FLIP and MCL1, which act at the level of
caspase-8 activation and mitochondria amplification of apoptosis
(Lemke et al, 2014a). In addition, E-cadherin may also discriminate
between the cells that respond to TRAIL therapy (Lu et al, 2014).
Our results indicate that, by facilitating the ubiquitination and acti-
vation of caspase-8, TP53INP2 is another potential biomarker for
TRAIL treatment (Fig 7). It would be interesting to see the expres-
sion of CDK9 in cancer cells with high levels of TP53INP2 and
address whether CDK9 inhibition would synergistically increase
sensitivity to TRAIL treatment. TRAIL therapy alone is clearly not
effective. In this regard, it is important to simultaneously target
several factors that cause TRAIL resistance and/or to increase the
sensitivity of cancer cells to apoptosis. This strategy is critical since
TRAIL administration could have pro-tumorigenic functions in some
types of cancer, such as KRAS-mutated cancer (von Karstedt et al,
2015; Pal et al, 2016).
We report that TP53INP2 belongs to those proteins with dual
functions in autophagy and apoptosis, which also include ATG5,
ATG4D, Beclin 1, p62, and AMBRA1 among others (Yousefi et al,
2006; Cho et al, 2009; Laussmann et al, 2011; Huang et al, 2013;
Strappazzon et al, 2016). TP53INP2 promotes autophagosomal
formation and activates autophagy flux in different cell types
(Nowak et al, 2009; Mauvezin et al, 2010; Sala et al, 2014; Romero
et al, 2018). In this study, we show that TP53INP2 acts also as a
switch at the level of caspase-8 activation, favoring death receptor-
mediated apoptosis. This effect of TP53INP2 promoting caspase-8
activation does not require autophagy machinery, probably because
TP53INP2 function in death receptor signaling is upstream from
autophagy. Once caspase-8 is activated, it cleaves TP53INP2 at LIR
sequence and prevents its role in autophagy, thus further promoting
apoptosis and downregulating the pro-survival role of autophagy. It
will be interesting to see how other stresses (not death ligands)
influence TP53INP2 function in apoptosis/autophagy cross-talk
(Fig 8)7 .
Taken together, our data reveal an unexpected role of TP53INP2
in the regulation of death receptor signaling. The mechanism
involves the scaffolding function of TP53INP2 and facilitates
caspase-8 ubiquitination by TRAF6, thereby switching or shifting
death receptor signaling toward apoptosis. This finding unveils an
additional point of apoptosis regulation that can be explored in
TRAIL therapy.
Materials and Methods
Plasmid constructs
We used following constructs: pCDNA3-FLAG-TP53INP2, pCMV-
FLAG-TRAF6 was a gift from John Kyriakis (Addgene 21624),
pCMV-FLAG-TRAF6 C70A, HA-Ub was a gift from Edward Yeh
(Addgene 18712), His-Ub was a gift from Astar Winoto (Addgene
31815), HA-Ub K48 was a gift from Ted Dawson (Addgene 17605),
HA-Ub K63 was a gift from Ted Dawson (Addgene17606), XPRESS-
caspase-8-NCC (kind gift from A. Ashkenazi), FLAG-caspase-8 (kind
gift from A. Ashkenazi), FLAG-caspase-8-Ub6 (kind gift from A.
Ashkenazi), FLAG-caspase-8-Ub9 (kind gift from A. Ashkenazi),
pCDNA3-TP53INP2, pCDNA3-TP53INP2 TIM mutant, pCDNA3-
TP53INP2 3KR mutant, pCDNA3-TP53INP2 LIR mutant, pCDNA3-
TP53INP2 3DE mutant, HA-p62 was a gift from Qing Zhong
(Addgene 28027), and myc-caspase-3 C163A was a gift from Guy
Salvesen (Addgene 11814). All mutations were done with the Quick
Mutagenesis Kit by Promega, following the manufacturer’s instruc-
tions, and the sequences were verified by DNA sequencing.
Cell culture
HeLa, HEK293T, MCF7, MDA-MB-231, MDA-MB-468, SKBr3, Huh7,
PLC, Hep3B, and MEF TRAF6 KO (kind gift from Manolis Paspar-
akis) cells were grown in DMEM (Gibco) supplemented with 10%
fetal bovine serum (FBS, Sigma); BT20 cells were grown in MEM
supplemented with 10% FBS; T47D and BT474 cells were grown in
RPMI (Gibco) supplemented with 10% FBS; and Snu449, HLE, and
HLF cells were cultured in RPMI with 10% FBS and 1% NEAA
(Sigma). Flp-In T-REx 293 cells expressing HA-FLAG-TP53INP2
were made following the manufacturer’s instructions (Thermo
Fisher Scientific). Staurosporine, doxorubicin, and actinomycin D
were from Sigma, bafilomycin A1 from Santa Cruz, cisplatin from
Ebewe Pharma, nec-1 from Enzo Life Sciences, zVAD-fmk from
Bachem, FasL and TNFa from Milipore, TRAIL from R&D Systems,
and CHX from Calbiochem. Nec-1 and z-VAD-fmk were added 2 h
before the induction of apoptosis.
Mouse model
The L-KO DOR mouse line was generated by crossing homozygous
TP53INP2 loxP/loxP mice with a mouse strain expressing Cre
recombinase under the control of the albumin promoter. Mice were
in a C57BL/6J pure genetic background. Non-expressing Cre
TP53INP2loxP/loxP littermates were used as controls for knockout
animals. Twelve- to 16-week-old mice were used in all experiments.
All animal experiments were done in compliance with guidelines
established by the University of Barcelona Committee on Animal
Care. Mice were kept under a 12-h dark–light period and provided
with a standard chow-diet and water ad libitum. For FasL treatment,
mice were injected i.p. with 0.15 lg/g body weight and sacrificed
4 h later. For doxorubicin (30 mg/kg body weight) and cisplatin
(20 mg/kg body weight), mice were injected i.p. and sacrificed 48 h
later.
Immunohistochemistry and immunofluorescence in liver sections
For immunohistochemistry and immunofluorescence assays, livers
were fixed in PFA 4% o/n at room temperature. After two washes
in PBS for 5 min, sections were incubated in NH4Cl (50 mM) and
glycine (20 mM) to reduce the autofluorescence and permeabilized
by incubating them with a solution of 0.1% Triton X-100 in 0.1%
sodium citrate for 2 min at 4°C. After two washes in PBS for 5 min
and blocking during 30 min in 10% FBS in PBS, slides were incu-
bated with Tom20 (Santa Cruz) and cytochrome c (BD Pharmingen)
ª 2019 The Authors The EMBO Journal e99300 | 2019 15 of 19
Saska Ivanova et al The EMBO Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
in blocking solution for 2 h. After three 10 min washes in PBS,
samples were further incubated in donkey anti-guinea pig Alexa-
Fluor 568 conjugated secondary antibodies (Invitrogen) for 1 h,
followed again by three 10 min washes in PBS. Hoechst33342 (1/
2,000; Molecular Probes) was used to label DNA. Sections were kept
in the dark after secondary antibody incubation. Slides were finally
covered using Fluoromount (Sigma) and allowed to dry o/n before
being stored at 4°C. A Leica TCS SP5 confocal scanning microscope
was used to analyze the immunofluorescence. TUNEL staining to
detect apoptosis was performed according to the manufacturer’s
instructions (In Situ Cell Death Detection Kit Fluorescein, Roche).
For light microscopy, sections were stained with hematoxylin and
eosin or cleaved caspase-3 following standard protocols.
Caspase-3 protein expression and cleavage assay
Recombinant caspase-3 was expressed in Escherichia coli and puri-
fied as described previously (77)8 . Caspase cleavage assays were
performed in 20 mM Hepes buffer, pH 7.2, containing 100 mM
NaCl, 10 mM dithiothreitol, 1 mM EDTA, 0.1 (w/v) CHAPS, and
10% (w/v) sucrose at 37°C. Briefly, caspases were incubated for
5 min in the reaction buffer at 37°C prior to the addition of lysates
overexpressing wild-type TP53INP2 or 3DE mutant to the final
volume of 25 ll. The final concentration of caspases was 1 lM.
After 1-h incubation with caspases, the reactions were terminated
by the addition of l× SDS loading buffer and boiling. The reaction
mixtures were analyzed by 12% SDS–PAGE gels and Western blot.
Immunoblotting
Cells were collected at the times indicated in the text post-induction
of apoptosis and incubated in RIPA buffer [50 mM Tris (pH 8.0),
100 mM NaCl, 0.1% (w/v) SDS, 1% (v/v) Nonident P-40, 0.5%
(w/v) deoxycholic acid, 1 mM EDTA] for 10 min on ice. Insoluble
material was removed by centrifugation at 14,000 rpm9 for 10 min.
Pierce assay (Promega) was used to determine protein concentra-
tion, and 50 lg of protein was resolved in 10 or 12% SDS–PAGE
gels. After transfer to PVDF membrane (Millipore), blots were
probed with antibodies against PARP (Cell Signaling), caspase-3
(Cell Signaling), cleaved caspase-3 (Cell Signaling), caspase-8 (Cell
Signaling, BD Pharmingen), p62 (Progen), DR4 (Cell Signaling),
DR5 (Cell Signaling), LC3 (MBL International), TP53INP2 (made in
our laboratory), TRAF6 (Cell Signaling), FLAG (Sigma), XPRESS
(Invitrogen), Bcl-2 (Santa Cruz), Bid (Cell Signaling), Mcl-1 (Cell
signaling), Bcl-xl (Santa cruz), Bak (Santa Cruz), Bax (Cell Signal-
ing), actin (Sigma), myc (Santa Cruz), and appropriate HRP-conju-
gated secondary antibodies (Jackson) and visualized with ECL
following the manufacturer’s instructions (Amersham). Cell frac-
tionation was done with NE-PER Nuclear and Cytoplasmic Extrac-
tion Reagents Kit (Thermo Fisher) following manufacturer’s
instructions.
Immunoprecipitation and pull-down assay
Cells were transfected with the indicated plasmids with polyethyle-
neimine (PEI) from Polysciences Inc., lysed for 36 h after transfec-
tion in lysis buffer and subjected to pull-down assays with FLAG
(Sigma), Nickel (Invitrogen), or HA (Sigma) resin, following the
manufacturer’s instructions. For denaturing pull-down, 6M urea
was added to the lysis buffer. Immunocomplexes were separated by
SDS–PAGE and detected by Western blot analysis. For endogenous
immunoprecipitation, cells were incubated or not with 100 ng/ml of
TRAIL for 30 min. Afterward, cells were cross-linked with formalde-
hyde (PanReac AppliChem) for 10 min, scraped and washed with
PBS. Cell lysis was performed with FLAG lysis buffer, and super-
natants were added to the protein G sepharose beads (Sigma) previ-
ously incubated with normal mouse IgG (Sigma) or anti-caspase-8
mouse antibody (BD Pharmingen). Primary antibodies were cross-
linked to protein G sepharose by DMP (Thermo Fisher) following
manufacturer’s instructions, and immunocomplexes were eluted
with glycine (pH = 3). For recombinant proteins pull-downs, FLAG-
caspase-8, TP53INP2, and FLAG-TP53INP2 were in vitro translated
with Promega’s TNT in vitro translation system and GST (Abcam)
and GST-TRAF6 (Abnova) were purchased. Recombinant proteins
were subjected to pull-down with FLAG (Sigma) resin, following
manufacturer’s instructions.
DEVDase activity and FACS analysis
30 lg of protein of untreated and treated cells in the presence or
absence of inhibitors was used to determine caspase activity by
measuring the cleavage of fluorogenic substrate Ac-DEVD-AFC
(Bachem) using Tecan.
For flow cytometry, cells were harvested at the indicated times
after treatment. Culture medium supernatant and PBS washes were
retained to ensure that both floating and adherent cells were
analyzed. After incubation for 15 min with Annexin V Alexa-647
(Invitrogen) following the manufacturer’s instructions, and propid-
ium iodide, cells were subjected to FACS analysis.
Fluorescence microscopy
Cells grown on coverslips for the indicated treatments were washed
with PBS and fixed in 4% paraformaldehyde (Santa Cruz) for 10 min,
followed by permeabilization with 0.2% (v/v) Triton X-100 in PBS
for 15 min. After extensive washing with PBS, cells were incubated
with primary antibodies for 1 h on room temperature. Following an
additional round of extensive washing with PBS, cells were incubated
either with goat anti-rabbit Alexa-647 or goat anti-mouse Alexa-488
antibody (Molecular Probes) for 60 min at room temperature. After
incubation, cells were washed with PBS, mounted on slides with
Fluoromount (Sigma), and visualized by confocal microscope
(Leica). Hoechst (Sigma) was used to stain the nuclei. For live cell
imaging, HeLa cells were transfected with TP53INP2-RFP and wide-
field images of live cells were captured using an Olympus 1X81
microscope in an imaging chamber with CO2 and temperature
control. Scans were taken every 5 min for approximately 3 h. TRAIL
(100 ng/ml) was added after second frame was taken.
Knock-down and CRISPR technology
HeLa cells were transfected with lentiviruses with shRNA for ATG5,
p62, and caspase-8 with PEI, and 48 h after exposed to puromycin
selection. The level of knock-down was analyzed by Western blot.
To knock out TRAF6, ATG7, and TP53INP2, we used a CRISPR tech-
nology. For TRAF6 and TP53INP2, the CRISPR plasmids were
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bought from Santa Cruz and done according to manufacturer’s
instructions. Forward and reverse oligonucleotides containing the
guide sequence to Atg7 (Forward 1: CACCGGAAGCTGAACGAGTAT
CGGC, Reverse 1: AAACGCCGATACTCGTTCAGCTTCC; Forward 2:
CACCGAACTCCAATGTTAAGCGAGC; Reverse 2: AAACGCTCGCT
TAACATTGGAGTTC) and TP53INP2 (Forward 1: CACCGCTCTGGT
TCTTGGACCGGCG, Reverse 1: AAACCGCCGGTCCAAGAACCAGA
GC; Forward 2: CACCGACCGGCGCGGACGGCTCTCG; Reverse 2: A
AACCGAGAG CCGTCCGCGC CGGTC) were annealed and cloned
into the pX330 plasmid (Cong et al, 2013) that was subsequently
transfected into HeLa cells using NanoJuice (NanoJuiceTM Transfec-
tion Kit, Novagen). GFP-positive cells were sorted 24 h after trans-
fection (BD FACSAria III SORP) and grown as single clones.
Screening for Atg7-KO and TP53INP2-KO cells was carried out by
Western blotting.
In vitro ubiquitination
In vitro ubiquitination assays were performed with the following
components: immunoprecipitated XPRESS-caspase-8-NCC, FLAG-
TP53INP2 and FLAG-TRAF6 (E3), UbcH13 (E2) and ubiquitin acti-
vating kit (Enzo), following the manufacturer’s instructions10 .
Statistics
Microsoft Office Excel was used for data analysis. Student’s t-tests
were used to compare results between two groups. Data were
presented as mean with standard error of the mean (SEM). P
values < 0.05 were considered significant.
Expanded View for this article is available online.
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